OncoSec Medical Inc (ONCSQ)

[InTheTrenches]

I was mistaken in this statement from my earlier post:

Further, I believe Keytruda has only an 18% complete response rate in first-line melanoma

---------------------------------

In reviewing the Keytruda label document, Keytruda was compared against Yervoy in a phase 3 trial for approval (Yervoy-naive patients):

Keytruda: CRR (Complete Response): 5-6%, BORR (Complete+Partial): 33-34%
Yervoy: CRR: 1%, BORR: 12%

EP IL-12 +
Keytruda: CRR: >40%, BORR: >50%
(Refractory/Relapse, Open Label, Patients predicted to be Keytruda non-responders)

Keytruda label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125514s012lbl.pdf
(page 17-18)